Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: pacman who wrote (362)	10/6/1999 7:12:00 PM
From: Thomas Kirwin	Respond to of 422

Earnings Alert - Net Revenue UP 94% Wednesday October 6, 9:17 am Eastern Time Immucor Announces Results For First Quarter; 94% Increase in Net Income NORCROSS, Ga., Oct. 6 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD - news), a leading provider of blood bank reagents and related products, announced a 94% increase in net income for the fiscal first quarter ended August 31, 1999, compared to the same period last year. For the quarter, net income increased to $1.2 million from $0.6 million for the same period last year. Diluted earnings per share rose 75% to $0.14 on 8.8 million weighted average shares outstanding from $0.08 on 8.3 million weighted average shares outstanding for the same period last year. Sales for the quarter rose 82% to a record $18.9 million from $10.4 million for the same period in 1998. The acquisitions of Gamma Biologicals and assets of the BCA division of Biopool contributed approximately $6.4 million to the sales increase while instrument sales added $1.9 million. Commenting on the results, Edward L. Gallup, president and chief executive officer of Immucor, said, ''I am extremely pleased with the growth in revenues and earnings that have resulted from our acquisition strategy and our transition into an instrument/systems company. We have grown the business substantially in spite of a soft quarter from our German and Canadian affiliates. These units combined for a revenue shortfall of almost $0.4 million compared with the same quarter last year, but we believe this dip to be temporary in nature. In addition, instrument sales were $0.3 million lower than expected because customers were unable to attend training sessions due to summer vacations. These customers were trained in September and revenue will be recognized in the second quarter. Mr. Gallup further commented, ''We remain very encouraged by our customers' acceptance of our systems and the positive impact we are having in the market place. As previously announced, we also look forward to the positive results from our North American launch of ReACT, Immucor's patented immunoreactive micro-bead technology which offers our small to medium sized customers a choice of solutions to meet their unique requirements.'' Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments. For more information on Immucor, please visit our website at immucor.com This press release contains forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. In particular, statements concerning future growth in sales and earnings are forward-looking statements, and it is not certain those things will occur. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10-Q.

To: pacman who wrote (362)	11/3/1999 7:08:00 AM
From: Thomas Kirwin	Respond to of 422

Immucor Announces Launch of ABS2000 in Japan Tuesday November 2, 8:29 am Eastern Time NORCROSS, Ga., Nov. 2 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD - news), a leading provider of blood bank reagents and related products, announced today that its exclusive distributor in Japan, Sanko Junyaku Co. Ltd., has received approval from the Japanese Ministry of Health to market the ABS2000 and the related reagents in Japan. The product will be launched immediately. The ABS2000 is the flagship of the Immucor family of products and the only instrument of its kind offering fully automated blood bank analysis for the hospital transfusion service. It is the only fully automated blood bank system cleared for market by the Food and Drug Administration. ''We believe the instrument is a very good fit for the hospital market in Japan and are extremely pleased with the commitment Sanko has made to the ABS2000,'' said Edward L. Gallup, Immucor president and chief executive officer. ''Sales of the ABS2000 and its reagents in Japan should begin to contribute significantly to operating earnings during the remainder of fiscal 2000.'' The ABS2000 is a closed system instrument and relies upon Immucor's patented ''solid phase technology'' for its operation. Each ABS2000 placement can generate up to $25,000 per annum in recurring reagent sales. ''Sanko is very dedicated to the success of the ABS2000 in their marketplace,'' Gallup continued. ''They have put a tremendous amount of effort into this product launch. Sanko has a proven track record for introducing new products to the Japanese market, growing Immucor's proprietary manual solid phase technology sales to $600,000 in the first year of introduction. Japan has the most developed healthcare system in Asia and is the third largest marketplace for diagnostics in the world, a huge untapped opportunity for Immucor and Sanko.'' Commenting on the launch of the ABS2000 in Japan, Mr. Ryo Watanabe, President of Sanko Junyaku, stated, ''We have access to the world's only FDA cleared, fully automated instrument. We are convinced that there is a very large potential for placements as the Japanese healthcare system is anxious to automate.'' Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation, which provides solutions for all segments of the market. For more information on Immucor, please visit the company's website at www.immucor.com . Sanko Junyaku Co. Ltd. occupies a leading position in the marketing of blood bank and diagnostic reagents and instruments in Japan. They are recognized for a strong direct distribution network in addition to a reputation for quality products and service. This press release may contain forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. In particular, statements concerning projected instrument placements are forward-looking statements and it is not certain this will occur. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward- looking statements. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10-Q. SOURCE: Immucor, Inc.

To: pacman who wrote (362)	1/4/2000 6:55:00 PM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Immucor Announces Record Results for Second Quarter Second Quarter Highlights - Net Income Increases 101% - Total Revenues Up 48% - Instrument Revenues Grow 125% Tuesday January 4, 6:05 pm Eastern Time NORCROSS, Ga., Jan. 4 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD - news), the global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced record growth in revenues and net income for the fiscal second quarter and six months ended November 30, 1999, compared to the same periods last year. Revenues for the fiscal second quarter rose 48 percent to $20.3 million, from $13.7 million in the same period last year. Net income for the quarter doubled to $1.4 million, from $0.7 million for the same quarter last year. Diluted earnings per share rose 89 percent to $0.17 on 8.6 million weighted average shares outstanding, from $0.09 on 7.9 million weighted average shares outstanding for the same period last year. ''The record growth in revenues reflects our aggressive strategy to consolidate the blood transfusion market, as well as a strong performance by our instrument sales group,'' commented Edward L. Gallup, president and chief executive officer. ''We added over $4 million in revenues from acquisitions during the quarter. Instrument revenues were up 125 percent, climbing to a record $3.6 million, signaling a growing acceptance of our automated solutions in the market place. While worldwide reagent sales were up 38%, a relatively strong US dollar reduced foreign sales by approximately $0.7 million dollars.'' For the six months ended November 30, 1999, revenues totaled a record $39.2 million, an increase of 63 percent over the $24.0 million in the same period in fiscal 1999. The acquisitions of Gamma Biologicals and assets of the BCA division of Biopool International Inc., contributed approximately $10.4 million of the sales increase, while instrument sales added $3.5 million. Total instrument sales in Fiscal 2000 have grown to $5.5 million. Year-to-date net income doubled, growing to $2.7 million from $1.3 million last year. Diluted earnings per share rose 82 percent to $0.31 on 8.7 million weighted average shares outstanding from $0.17 on 8.1 million weighted average shares outstanding for the same six-month period last year. Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit the Company's website at immucor.com . This press release contains forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this document are based on information available to the Company on the date hereof and the Company assumes no obligation to update any such forward-looking statements. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 1O-K and Quarterly Reports on Form 1O-Q.